Skip Navigation LinksHome > March 2013 - Volume 35 - Issue 2 > Osteosarcoma After Bone Marrow Transplantation
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3182677f19
Original Articles

Osteosarcoma After Bone Marrow Transplantation

Ueki, Hideaki MD*,†; Maeda, Naoko MD, PhD*; Sekimizu, Masahiro MD*; Tsukushi, Satoshi MD, PhD; Nishida, Yoshihiro MD, PhD; Horibe, Keizo MD, PhD*

Collapse Box

Abstract

Three children treated with bone marrow transplantation for acute lymphoblastic leukemia, Diamond-Blackfan anemia, and congenital amegakaryocytic thrombocytopenia developed secondary osteosarcoma in the left tibia at the age of 13, 13, and 9 years, respectively, at 51, 117, and 106 months after transplantation, respectively. Through treatment with chemotherapy and surgery, all 3 patients are alive without disease. We surveyed the literature and reviewed 10 cases of osteosarcoma after hematopoietic stem cell transplantation (SCT), including our 3 cases. Eight of the patients had received myeloablative total body irradiation before SCT. The mean interval from SCT to the onset of osteosarcoma was 6 years and 4 months, and the mean age at the onset of osteosarcoma was 14 years and 5 months. The primary site of the post-SCT osteosarcoma was the tibia in 6 of 10 cases, in contrast to de novo osteosarcoma, in which the most common site is the femur. At least 7 of the 10 patients are alive without disease. Osteosarcoma should be one of the items for surveillance in the follow-up of patients who undergo SCT.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.